A Phase 3 interventional study of Lidocaine in Cancer and Pain, sponsored by Gustave Roussy, Cancer Campus, Grand Paris. Status unknown at 1 site in France. Open to participants aged 6 Years to 70 Years. Per ClinicalTrials.gov, last updated 2007-09-19.
Sponsored by Gustave Roussy, Cancer Campus, Grand Paris · Phase 3, Interventional, and Treatment
This study will evaluate the benefit of lidocaine perfusion in cancer related visceral pain resistant to morphinics. It is an efficacy study in adults and children and a randomized prospective study.
46 studies on the registry are indexed under Visceral Pain; 16 are open to participants now.
This study's planned enrollment of 100 is above the median of 68 across 42 interventional studies indexed under Visceral Pain.
Browse Visceral Pain studies →Gustave Roussy, Cancer Campus, Grand Paris is the lead sponsor of 242 studies on the registry; 65 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
To determine prospectively the lidocaine efficacy in 2 types of patient populations with cancer (group A: children from 6 to 14 years old and group B: adults from 15 to 70 years old)
Time frame: continuous intravenous perfusion for 6 days
To confirm the tolerance of the lidocaine
This study is status unknown, as verified in Sep 2006. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gustave Roussy, Cancer Campus, Grand Paris